AC Immune Announces Pricing of Underwritten Offering of Common Shares
AC Immune Announces Pricing of Underwritten Offering of Common Shares
Lausanne,
The Company expects the gross proceeds from the offering, before deducting the underwriting discounts and commissions and other offering expenses, to be approximately
The equity offering was led by
The Company plans to use the proceeds from the offering, together with existing liquidity, primarily to strategically invest in research and clinical development of its current pipeline, its technology platforms, working capital, capital expenditures and general corporate purposes.
Delivery of the common shares of the Company against payment of the offering price is expected to be made on or about
The offering was made pursuant to an effective shelf registration statement of the Company previously filed with the
The offering, sale and purchase of the common shares of the Company are subject to market and other conditions and the restrictions set forth in the Company’s articles of association and may be subject to certain restrictions under applicable laws and regulations. There can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
Disclaimer
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any securities, in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. This press release is not an offer to sell or a solicitation of offers to purchase or subscribe for shares, nor a prospectus within the meaning of Swiss Financial Services Act and not a prospectus under any other applicable laws. Copies of this press release may not be sent to jurisdictions, or distributed in or sent from jurisdictions, in which this is barred or prohibited by law.
About
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are made under the “safe harbor” provisions of The Private Securities Litigation Reform Act of 1995, including AC Immune’s expectations regarding the consummation of the public offering and anticipated use of proceeds. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include, without limitation, risks and uncertainties related to the satisfaction of customary closing conditions related to the public offering. There can be no assurance that
For further information, please contact:
Head of Investor Relations & Corporate Communications Phone: +41 21 345 91 91 Email: gary.waanders@acimmune.com |
U.S. Investors Phone: +1 212 915 2577 Email: cdavis@lifesciadvisors.com |
International Media Phone: +41 79 367 6254 Email: chris.maggos@cohesionbureau.com |
Attachment
![](https://ml-eu.globenewswire.com/media/MTZkMGJhMWItMGQ5My00NDY2LThmOTktYmMzMjVkODg0YzFhLTEwMzc0NDM=/tiny/AC-Immune-SA.png)
Source: AC Immune SA